WO2004011544A1 - Ophtalmic compositions - Google Patents

Ophtalmic compositions Download PDF

Info

Publication number
WO2004011544A1
WO2004011544A1 PCT/US2003/023781 US0323781W WO2004011544A1 WO 2004011544 A1 WO2004011544 A1 WO 2004011544A1 US 0323781 W US0323781 W US 0323781W WO 2004011544 A1 WO2004011544 A1 WO 2004011544A1
Authority
WO
WIPO (PCT)
Prior art keywords
solution
percent
weight
concentration
buffered
Prior art date
Application number
PCT/US2003/023781
Other languages
French (fr)
Inventor
Shih-Horng Su
George W. Ousler, Iii
Min-Shyan Sheu
Original Assignee
Ast Products, Inc.
Ophthalmic Research Associates, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/207,375 external-priority patent/US6828356B2/en
Priority claimed from US10/207,376 external-priority patent/US6806364B2/en
Application filed by Ast Products, Inc., Ophthalmic Research Associates, Inc. filed Critical Ast Products, Inc.
Priority to AU2003259301A priority Critical patent/AU2003259301A1/en
Priority to CA002494449A priority patent/CA2494449A1/en
Publication of WO2004011544A1 publication Critical patent/WO2004011544A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08Cellulose derivatives
    • C08L1/26Cellulose ethers
    • C08L1/28Alkyl ethers
    • C08L1/284Alkyl ethers with hydroxylated hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/745Polymers of hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/42Phosphorus; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Definitions

  • Dry eye syndrome one of the most common eye disorders, is usually caused by a reduction of the quantity of tears produced or a decrease in the quality of the tear film that lubricates the eyes. Symptoms include itching, burning, irritation, redness, excessive tearing, blurred vision that improves with blinking, and increased discomfort after reading or watching TV.
  • An aspect of this invention relates to an aqueous ophthalmic solution containing 0.2 to 2.5 (e.g., 0.5 to 0.8) percent by weight a polymeric demulcent, 0.045 to 0.065 (e.g., 0.05 to 0.06) percent by weight a calcium salt, and 0.14 to 1.4 (e.g., 0.3 to 1.2) percent by weight a phosphate salt.
  • the ophthalmic solution has a viscosity of 20 to 150 (e.g., 50 to 90) centipoise and is buffered to a pH 5.5 to 8.5 (e.g., 6 to 8) with a phosphate salt or other suitable salts.
  • An effective amount of the above-described ophthalmic solution can be used to treat dry eye syndrome, and can also be used to treat another eye disorder if it contains a drug for that disorder. "An effective amount" is the amount which is required to confer remedial or therapeutic effect.
  • the ophthalmic solution of this invention when applied to the ocular surface of a subject, unexpectedly stays longer with the eye and, more importantly prolongs the integrity of the tear film.
  • the extraordinary efficacy of this solution is attributed to its unique composition and the unique method by which it is prepared.
  • the aqueous ophthalmic solution of this invention has a pH of 5.5 to 8.5 (e.g., 6.0 to 7.4) and a viscosity of 20 to 150 centipoise (e.g., 40-70 centipoise). It can be directly applied onto the ocular surface of a patient.
  • the aqueous ophthalmic solution contains a calcium salt (i.e., one or more calcium salts, such as calcium chloride and calcium phosphate), a phosphate salt (i.e., one or more phosphate salts, such as sodium phosphate and potassium phosphate), and a polymeric demulcent (i.e., one or more polymeric demulcents, such as polyvinyl alcohol, chitosan, and hydroxypropyl methylcellulose).
  • a calcium salt i.e., one or more calcium salts, such as calcium chloride and calcium phosphate
  • a phosphate salt i.e., one or more phosphate salts, such as sodium phosphate and potassium phosphate
  • a polymeric demulcent i.e., one or more polymeric demulcents, such as polyvinyl alcohol, chitosan, and hydroxypropyl methylcellulose.
  • the polymeric demulcent because of its high molecular weight, greatly contributes to the viscosity of the ophthalmic solution regardless of its degree of hydrophilicity or hydrophobicity. It is also capable of forming a matrix to reduce water evaporation after the ophthalmic solution is placed on an ocular surface.
  • suitable polymeric demulcents including both homopolymers and copolymers, are: cellulosic polymers (e.g., hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxybutyl methylcellulose, hydroxyethyl ethylcellulose, carboxymethyl hydroxyethylcellulose, methylcellulose, carboxymethylcellulose); polyols (e.g., polyethylene glycol 300, polyethylene glycol 400, and polysorbate 80); polysaccharides (e.g., gelatin, sodium hyaluronate, sodium alginate, chitosan, and dextran 70); poly(ethylene oxide); polyvinyl alcohol; povidone; and polyvinyl pyrrolidone.
  • cellulosic polymers e.g., hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxybutyl methylcellulose, hydroxyethyl ethylcellulose, carboxymethyl hydroxyethylcellulose,
  • the ophthalmic solution contains glycerol or propyleneglycerol. It may further contain glycine, magnesium chloride, and zinc chloride, all of which are found in natural tears. Sodium borate, a mild antiseptic, and other desirable ingredients may also be included. For obvious reasons, all of the ingredients contained in the solution of this invention must be ophthalmically compatible.
  • a polymeric demulcent is first dissolved in water or in an aqueous solution that contains one or more of the other ingredients (e.g., a phosphate salt), with the aid of an agitator and at room temperature or a slightly elevated temperature, i.e., 45°C or lower. More ingredients, if any, can then be added to the polymeric demulcent-containing solution. Also within the scope of this invention is dissolving the polymeric demulcent with some or all of the other ingredients at the same time.
  • the other ingredients e.g., a phosphate salt
  • the polymeric demulcent can be conveniently dissolved in a solution that is buffered with a phosphate salt (e.g., a phosphate buffered saline) and contains all the other ingredients.
  • a phosphate salt e.g., a phosphate buffered saline
  • pH 7.2 pH 7.2
  • calcium chloride as well as other ingredients, is dissolved. Any pH change is adjusted with drops of a concentrated NaOH or HC1 solution. Hydroxypropyl methylcellulose is then dissolved in the resultant solution in the manner described above.
  • an ophthalmic solution that contains 0.058 percent by weight calcium chloride, 0.6 to 0.8 percent by weight sodium and potassium phosphates, and 0.6 percent by weight hydroxypropyl methylcellulose can thus be obtained.
  • sodium chloride 9 g
  • sodium phosphate dibasic, 3.55 g
  • potassium phosphate dibasic, 3.40 g
  • calcium chloride 0.583 g
  • magnesium chloride 0.76 g
  • zinc chloride 0.0154 g
  • glycerol 10 g
  • sodium borate 0.10 g
  • glycine 0.075 g
  • sodium chloride, sodium phosphate and potassium phosphates are the components of phosphate buffered saline.
  • the solution was stirred at ambient temperature for 30 minutes, followed by pH adjustment with pyrogen-free NaOH (1 N) to 7.4 and filtration with a membrane (pore size 0.2 ⁇ m) to remove impurities.
  • 0.6 g of hydroxypropyl methylcellulose was added to the filtered solution.
  • the mixture was agitated (100 rpm) at 37°C until it became clear. The viscosity was measured and, if necessary, adjusted with the filtered solution.
  • TFBUT an index of the severity of dry eye syndrome, can be used to measure the efficacy of a solution in maintaining the tear film.
  • a patient's eye was first instilled with 5 microliters of 2% sodium fluorescein. After the fluorescein instillation, the patient placed his or her head in a slit lamp, and the investigator viewed the eye under cobalt blue illumination. The patient was instructed to blink three times and hold the eyes open at normal aperture after the third blink. A stop watch was started when the eye was opened on the third blink, and was stopped when the investigator identified a region of tear film break-up that had started to expand. This region of tear film break-up was identifiable by black voids in the otherwise green fluorescing tear film. The eye was video taped during the test.
  • the efficacy of the ophthalmic solution prepared above on the TFBUT in seven dry- eye patients was tested as follows: First, a TFBUT baseline for each patient was first established. One or two drops of the ophthalmic solution were then applied into one eye of each patient and the TFBUT was measured at 5, 10, 15, 30, 45, and 60 minutes after the application. The results show that the solution was much more efficacious in prolonging dry- eye patients' TFBUT than three commercial products.

Abstract

An aqueous ophthalmic solution containing 0.2 to 2.5 percent by weight a polymeric demulcent, 0.045 to 0.065 percent by weight a calcium salt, and 0.14 to 1.4 percent by weight a phosphate salt. The solution has a viscosity of 20 to 150 centipoise and is buffered to a PH 5.5 to 8.5.

Description

OPHTHALMIC COMPOSITIONS
BACKGROUND
Dry eye syndrome, one of the most common eye disorders, is usually caused by a reduction of the quantity of tears produced or a decrease in the quality of the tear film that lubricates the eyes. Symptoms include itching, burning, irritation, redness, excessive tearing, blurred vision that improves with blinking, and increased discomfort after reading or watching TV.
There is a correlation between aging and decreased production of eye oil (60% less at age 65 than at age 18). The oil deficiency affects the tear film. Without adequate oil to seal the watery layer, the tear film evaporates faster, leaving dry areas on the cornea. Hot, dry or windy climates, high altitudes, air conditioning, and cigarette smoke also cause dry eye.
A number of approaches exist for treating dry eye. For example, one can supplement the tear film with artificial tears. However, too many applications are often required over the course of the day.
SUMMARY
An aspect of this invention relates to an aqueous ophthalmic solution containing 0.2 to 2.5 (e.g., 0.5 to 0.8) percent by weight a polymeric demulcent, 0.045 to 0.065 (e.g., 0.05 to 0.06) percent by weight a calcium salt, and 0.14 to 1.4 (e.g., 0.3 to 1.2) percent by weight a phosphate salt. The ophthalmic solution has a viscosity of 20 to 150 (e.g., 50 to 90) centipoise and is buffered to a pH 5.5 to 8.5 (e.g., 6 to 8) with a phosphate salt or other suitable salts. It may further contain one or more of the following ingredients: 0.5 to 1.0 percent by weight glycerol, 0.5 to 1.0 percent by weight propyleneglycerol, 005 to 0.05 percent by weight glycine, 0.006 to 0.08 percent by weight sodium borate, 0.025 to 0.10 percent by weight magnesium chloride, and 0.001 to 0.01 percent by weight zinc chloride. An effective amount of the above-described ophthalmic solution can be used to treat dry eye syndrome, and can also be used to treat another eye disorder if it contains a drug for that disorder. "An effective amount" is the amount which is required to confer remedial or therapeutic effect.
Another aspect of this invention relates to a method of preparing polymeric demulcent-containing ophthalmic compositions, including those described above and others. The method includes immersing a polymeric demulcent in water or in an aqueous solution containing one or more ingredients (e.g., calcium chloride), agitating the water or the aqueous solution at 25°C, i.e., room temperature, to 45°C (e.g., 30°C to 45°C) until the polymeric demulcent is dissolved to form a polymeric demulcent-containing solution, and optionally adding one or more other ingredients to the polymeric demulcent-containing solution.
The ophthalmic solution of this invention, when applied to the ocular surface of a subject, unexpectedly stays longer with the eye and, more importantly prolongs the integrity of the tear film. The extraordinary efficacy of this solution is attributed to its unique composition and the unique method by which it is prepared.
Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
DETAILED DESCRIPTION
The aqueous ophthalmic solution of this invention has a pH of 5.5 to 8.5 (e.g., 6.0 to 7.4) and a viscosity of 20 to 150 centipoise (e.g., 40-70 centipoise). It can be directly applied onto the ocular surface of a patient.
The aqueous ophthalmic solution contains a calcium salt (i.e., one or more calcium salts, such as calcium chloride and calcium phosphate), a phosphate salt (i.e., one or more phosphate salts, such as sodium phosphate and potassium phosphate), and a polymeric demulcent (i.e., one or more polymeric demulcents, such as polyvinyl alcohol, chitosan, and hydroxypropyl methylcellulose).
The polymeric demulcent, because of its high molecular weight, greatly contributes to the viscosity of the ophthalmic solution regardless of its degree of hydrophilicity or hydrophobicity. It is also capable of forming a matrix to reduce water evaporation after the ophthalmic solution is placed on an ocular surface. Examples of suitable polymeric demulcents, including both homopolymers and copolymers, are: cellulosic polymers (e.g., hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxybutyl methylcellulose, hydroxyethyl ethylcellulose, carboxymethyl hydroxyethylcellulose, methylcellulose, carboxymethylcellulose); polyols (e.g., polyethylene glycol 300, polyethylene glycol 400, and polysorbate 80); polysaccharides (e.g., gelatin, sodium hyaluronate, sodium alginate, chitosan, and dextran 70); poly(ethylene oxide); polyvinyl alcohol; povidone; and polyvinyl pyrrolidone.
Optionally, the ophthalmic solution contains glycerol or propyleneglycerol. It may further contain glycine, magnesium chloride, and zinc chloride, all of which are found in natural tears. Sodium borate, a mild antiseptic, and other desirable ingredients may also be included. For obvious reasons, all of the ingredients contained in the solution of this invention must be ophthalmically compatible.
To prepare the ophthalmic solution of this invention, a polymeric demulcent is first dissolved in water or in an aqueous solution that contains one or more of the other ingredients (e.g., a phosphate salt), with the aid of an agitator and at room temperature or a slightly elevated temperature, i.e., 45°C or lower. More ingredients, if any, can then be added to the polymeric demulcent-containing solution. Also within the scope of this invention is dissolving the polymeric demulcent with some or all of the other ingredients at the same time. Of course, the polymeric demulcent can be conveniently dissolved in a solution that is buffered with a phosphate salt (e.g., a phosphate buffered saline) and contains all the other ingredients. For example, in a phosphate buffered saline, pH 7.2, calcium chloride, as well as other ingredients, is dissolved. Any pH change is adjusted with drops of a concentrated NaOH or HC1 solution. Hydroxypropyl methylcellulose is then dissolved in the resultant solution in the manner described above. With each ingredient in a pre- determined amount, an ophthalmic solution that contains 0.058 percent by weight calcium chloride, 0.6 to 0.8 percent by weight sodium and potassium phosphates, and 0.6 percent by weight hydroxypropyl methylcellulose can thus be obtained.
The same method can also be used to prepare other polymeric demulcent-containing ophthalmic solutions not within the scope of this invention. Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. The following example, which demonstrates how to prepare and test an ophthalmic solution of this invention, is therefore to be construed as merely illustrative and not limitative of the remainder of the disclosure in any way. EXAMPLE
To 1000 ml of pyro gen-free water, the chemicals were added in the following order: sodium chloride (9 g), sodium phosphate (dibasic, 3.55 g), potassium phosphate (monobasic, 3.40 g), calcium chloride (0.583 g), magnesium chloride (0.476 g), zinc chloride (0.0154 g), glycerol (10 g), sodium borate (0.10 g), and glycine (0.075 g). Among them, sodium chloride, sodium phosphate and potassium phosphates are the components of phosphate buffered saline. The solution was stirred at ambient temperature for 30 minutes, followed by pH adjustment with pyrogen-free NaOH (1 N) to 7.4 and filtration with a membrane (pore size 0.2 μm) to remove impurities. 0.6 g of hydroxypropyl methylcellulose was added to the filtered solution. The mixture was agitated (100 rpm) at 37°C until it became clear. The viscosity was measured and, if necessary, adjusted with the filtered solution.
The ophthalmic solution thus obtained was sterilized by filtration. When applied to the eye, it was found to stay for a much longer time than a solution of the same composition prepared by dissolving hydroxypropyl methylcellulose at 80°C. The solution was also subjected to a "tear film break-up time" or "TFBUT" test. TFBUT, an index of the severity of dry eye syndrome, can be used to measure the efficacy of a solution in maintaining the tear film.
In this TFBUT test, a patient's eye was first instilled with 5 microliters of 2% sodium fluorescein. After the fluorescein instillation, the patient placed his or her head in a slit lamp, and the investigator viewed the eye under cobalt blue illumination. The patient was instructed to blink three times and hold the eyes open at normal aperture after the third blink. A stop watch was started when the eye was opened on the third blink, and was stopped when the investigator identified a region of tear film break-up that had started to expand. This region of tear film break-up was identifiable by black voids in the otherwise green fluorescing tear film. The eye was video taped during the test.
The efficacy of the ophthalmic solution prepared above on the TFBUT in seven dry- eye patients was tested as follows: First, a TFBUT baseline for each patient was first established. One or two drops of the ophthalmic solution were then applied into one eye of each patient and the TFBUT was measured at 5, 10, 15, 30, 45, and 60 minutes after the application. The results show that the solution was much more efficacious in prolonging dry- eye patients' TFBUT than three commercial products.
OTHER EMBODIMENTS
It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, winch is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims

What is claimed is:
1. An aqueous ophthalmic solution, the solution comprising: 0.2 to 2.5 percent by weight a polymeric demulcent,
0.045 to 0.065 percent by weight a calcium salt, and 0.14 to 1.4 percent by weight a phosphate salt, wherein the solution has a viscosity of 20 to 150 centipoise and is buffered to a pH 5.5 to 8.5.
2. The solution of claim 1, wherein the solution is buffered with a phosphate salt.
3. The solution of claim 2, wherein the concentration of the calcium salt is 0.05 to 0.06 percent by weight.
4. The solution of claim 3, wherein the concentration of the polymeric demulcent is 0.5 to 0.8 percent by weight, the concentration of the phosphate salt is 0.3 to 1.2 percent by weight, and the solution has a viscosity of 50 to 90 centipoise and is buffered to a pH of 6.0 to 8.0.
5. The solution of claim 2, wherein the concentration of the calcium salt is 0.058 percent by weight.
6. The solution of claim 5, wherein the concentration of the polymeric demulcent is 0.5 to 0.8 percent by weight, the concentration of the phosphate salt is 0.3 to 1.2 percent by weight, and the solution has a viscosity of 50 to 90 centipoise and is buffered to a pH of 6.0 to 8.0.
7. The solution of claim 2, further comprising 0.5 to 1.0 percent by weight glycerol or propyleneglycerol.
8. The solution of claim 2, further comprising 0.5 to 1.0 percent by weight glycerol.
9. The solution of claim 8, wherein the concentration of the calcium salt is 0.05 to 0.06 percent by weight.
10. The solution of claim 9, wherein the concentration of the polymeric demulcent is 0.5 to 0.8, the concentration of the phosphate salt is 0.3 to 1.2 percent by weight, and the solution has a viscosity of 50 to 90 centipoise and is buffered to a pH of 6.0 to 8.0.
11. The solution of claim 2, wherein the polymeric demulcent is a cellulosic polymer.
12. The solution of claim 11, wherein the concentration of the calcium salt is 0.05 to 0.06 percent by weight.
13. The solution of claim 12, wherein the concentration of the cellulosic polymer is 0.5 to 0.8 percent by weight, the concentration of the phosphate salt is 0.3 to 1.2 percent by weight, and the solution has a viscosity of 50 to 90 centipoise and is buffered to a pH of 6.0 to 8.0.
14. The solution of claim 11, wherein the cellulosic polymer is hydroxy propylmethylcellulose.
15. The solution of claim 14, wherein the concentration of the calcium salt is 0.05 to 0.06 percent weight.
16. The solution of claim 15, wherein the concentration of the hydroxy propylmethylcellulose is 0.5 to 0.8 percent by weight, the concentration of the phosphate salt is 0.3 to 1.2 percent by weight, and the solution has a viscosity of 50 to 90 centipoise and is buffered to a H of 6.0 to 8.0.
17. The solution of claim 2, wherein the calcium salt is calcium chloride.
18. The solution of claim 17, wherein the concentration of the calcium chloride is 0.05 to 0.06 percent by weight.
19. The solution of claim 18, wherein the concentration of the polymeric demulcent is 0.5 to 0.8 percent by weight, the concentration of the phosphate salt is 0.3 to 1.2 percent by weight, and the solution has a viscosity of 50 to 90 centipoise and is buffered to a pH of 6.0 to 8.0.
20. The solution of claim 17, wherein the concentration of calcium chloride is 0.058 percent by weight.
21. The solution of claim 20, wherein the concentration of the polymeric demulcent is 0.5 to 0.8 percent by weight, the concentration of the phosphate salt is 0.3 to 1.2 percent by weight, and the solution has a viscosity of 50 to 90 centipoise and is buffered to a pH of 6.0 to 8.0.
22. The solution of claim 17, wherein the cellulosic polymer is a cellulosic polymer.
23. The solution of claim 22, further comprising 0.5 to 1.0 percent by weight glycerol.
24. The solution of claim 23, wherein the concentration of the calcium chloride is 0.05 to 0.06 percent by weight.
25. The solution of claim 24, wherein the concentration of the cellulosic polymer is 0.5 to 0.8 percent by weight, the concentration of the phosphate salt is 0.3 to 1.2 percent by weight, and the solution has a viscosity of 50 to 90 centipoise and is buffered to apH of 6.0 to 8.0.
26. The solution of claim 23, wherein the cellulosic polymer is hydroxypropyl methylcellulose.
27. The solution of claim 26, wherein the concentration of the calcium chloride is 0.058 percent by weight.
28. The solution of claim 27, wherein the concentration of the hydroxypropyl methylcellulose is 0.5 to 0.8 percent by weight, the concentration of the phosphate salt is 0.3 to 1.2 percent by weight, and the solution has a viscosity of 50 to 90 centipoise and is buffered to a pH of 6.0 to 8.0.
29. The solution of claim 28, wherein the concentration of the hydroxypropyl methylcellulose is 0.6 percent by weight, the concentration of the phosphate salt is 0.6 to 0.8 percent by weight, and the solution has a viscosity of 70 centipoise and is buffered to a pH of 6.0 to 7.4.
30. The solution of claim 29, further comprising: 0.005 to 0.05 percent by weight glycine,
0.006 to 0.08 percent by weight sodium borate,
0.025 to 0.10 percent by weight magnesium chloride, and
0.001 to 0.01 percent by weight zinc chloride.
31. The solution of claim 1, wherein the polymeric demulcent is a cellulosic polymer.
32. The solution of claim 31, wherein the concentration of the calcium salt is 0.05 to 0.06 percent by weight.
33. The solution of claim 32, wherein the concentration of the cellulosic polymer is 0.5 to 0.8 percent by weight, the concentration of the phosphate salt is 0.3 to 1.2 percent by weight, and the solution has a viscosity of 50 to 90 centipoise and is buffered to a pH of 6.0 to 8.0.
34. The solution of claim 33, further comprising 0.5 to 1.0 percent by weight glycerol.
35. The solution of claim 31, wherein the cellulosic polymer is hydroxypropyl methylcellulose.
36. The solution of claim 35, wherein the concentration of the calcium salt is 0.05 to 0.06 percent weight.
37. The solution of claim 36, wherein the concentration of the hydroxypropyl methylcellulose is 0.5 to 0.8 percent by weight, the concentration of the phosphate salt is 0.3 to 1.2 percent by weight, and the solution has a viscosity of 50 to 90 centipoise and is buffered to a pH of 6.0 to 8.0.
38. The solution of claim 37, further comprising 0.5 to 1.0 percent by weight glycerol.
39. A method for treating an eye, comprising administering to an eye in need thereof an effective amount of the solution of claim 1.
40. A method for treating an eye, comprising administering to an eye in need thereof an effective amount of the solution of claim 31.
41. A method for treating an eye, comprising administering to an eye in need thereof an effective amount of the solution of claim 34.
42. A method for treating an eye, comprising administering to an eye in need thereof an effective amount of the solution of claim 35.
43. A method for treating an eye, comprising admimstenng to an eye in need thereof an effective amount of the solution of claim 38.
44. A method of preparing a polymeric demulcent-containing ophthalmic composition, said method comprising: immersing a polymeric demulcent in water or in an aqueous solution containing one or more ingredients, agitating the water or solution at 25 to 45°C until the polymeric demulcent is dissolved to form a polymeric demulcent-containing solution, and optionally adding one or more other ingredients to the polymeric demulcent- containing solution.
45. The method of claim 44, wherein the agitating step is performed at 30 to 45°C.
46. The method of claim 45, wherein the immersing step is performed by placing the polymeric demulcent in an aqueous solution containing calcium chloride.
47. The method of claim 45, wherein the immersing step is performed by placing the polymeric demulcent in an aqueous solution containing all other ingredients.
48. The method of claim 46, wherein the aqueous solution contains a phosphate salt.
49. The method of claim 48, wherein the aqueous solution is a phosphate buffered solution.
50. The method of claim 47, wherein the aqueous solution contains a phosphate salt.
51. The method of claim 50, wherein the aqueous solution is a phosphate buffered solution.
52. The method of claim 44, wherein the polymeric demulcent is a cellulosic polymer.
53. The method of claim 52, wherein the agitating step is performed at 30 to 45°C.
54. The method of claim 53, wherein the immersing step is performed by placing the cellulosic polymer in an aqueous solution containing calcium chloride.
55. The method of claim 53, wherein the immersing step is performed by placing the cellulosic polymer in an aqueous solution containing all other ingredients.
56. The method of claim 54, wherein the aqueous solution contains a phosphate salt.
57. The method of claim 56, wherein the aqueous solution is a phosphate buffered solution.
58. The method of claim 55, wherein the aqueous solution contains a phosphate salt.
59. The method of claim 58, wherein the aqueous solution is a phosphate buffered solution.
60. The method of claim 52, wherein the cellulosic polymer is hydroxypropyl methylcellulose.
61. The method of claim 52, wherein the agitating step is performed at 30 to 45°C.
62. The method of claim 61, wherein the cellulosic polymer is hydroxypropyl methylcellulose.
63. The method of claim 62, wherein the immersing step is performed by placing the hydroxypropyl methylcellulose in an aqueous solution containing calcium chloride.
64. The method of claim 62, wherein the immersing step is performed by placing the hydroxypropyl methylcellulose polymer in an aqueous solution containing all other ingredients.
65. The method of claim 63, wherein the aqueous solution contains a phosphate salt.
66. The method of claim 65, wherein the aqueous solution is a phosphate buffered solution.
67. The method of claim 64, wherein the aqueous solution contains a phosphate salt.
68. The method of claim 67, wherein the aqueous solution is a phosphate buffered solution.
PCT/US2003/023781 2002-07-29 2003-07-29 Ophtalmic compositions WO2004011544A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003259301A AU2003259301A1 (en) 2002-07-29 2003-07-29 Ophtalmic compositions
CA002494449A CA2494449A1 (en) 2002-07-29 2003-07-29 Ophtalmic compositions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/207,375 US6828356B2 (en) 2002-07-29 2002-07-29 Preparation of ophthalmic compositions
US10/207,376 US6806364B2 (en) 2002-07-29 2002-07-29 Ophthalmic compositions
US10/207,375 2002-07-29
US10/207,376 2002-07-29

Publications (1)

Publication Number Publication Date
WO2004011544A1 true WO2004011544A1 (en) 2004-02-05

Family

ID=31190685

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/023781 WO2004011544A1 (en) 2002-07-29 2003-07-29 Ophtalmic compositions

Country Status (3)

Country Link
AU (1) AU2003259301A1 (en)
CA (1) CA2494449A1 (en)
WO (1) WO2004011544A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007532563A (en) * 2004-04-07 2007-11-15 カリプシス・インコーポレーテッド Arylsulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578578A (en) * 1984-11-13 1996-11-26 Alcon Laboratories, Inc. Ophthalmic solutions
US5807585A (en) * 1988-08-04 1998-09-15 Ciba Vision Corporation Method of preserving ophthalmic solution and compositions therefor
US5888493A (en) * 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
US6265444B1 (en) * 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
US6297228B1 (en) * 1991-11-22 2001-10-02 Alcon Manufacturing, Ltd. Use of angiostatic steroids in photodynamic therapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578578A (en) * 1984-11-13 1996-11-26 Alcon Laboratories, Inc. Ophthalmic solutions
US5807585A (en) * 1988-08-04 1998-09-15 Ciba Vision Corporation Method of preserving ophthalmic solution and compositions therefor
US6297228B1 (en) * 1991-11-22 2001-10-02 Alcon Manufacturing, Ltd. Use of angiostatic steroids in photodynamic therapy
US5888493A (en) * 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
US6265444B1 (en) * 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007532563A (en) * 2004-04-07 2007-11-15 カリプシス・インコーポレーテッド Arylsulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders

Also Published As

Publication number Publication date
AU2003259301A1 (en) 2004-02-16
CA2494449A1 (en) 2004-02-05
AU2003259301A8 (en) 2004-02-16

Similar Documents

Publication Publication Date Title
US6806364B2 (en) Ophthalmic compositions
CA2468771C (en) Pharmaceutical composition for use in ophthalmology and rhinology
US6828356B2 (en) Preparation of ophthalmic compositions
TWI361701B (en) Ophthalmic formulation for the prevention and treatment of adverse ocular conditions, particularly those associated with the aging eye
JP5542674B2 (en) Eye drop composition based on tamarind seed polysaccharide and hyaluronic acid
CN101312711B (en) Pharmaceutical composition free from dexpanthenol, calcium ions, and phosphate, and use of calcium chelating agent and ophthalmologically compatible viscosity regulator
Posarelli et al. Cross-linked hyaluronic acid as tear film substitute
EA001067B1 (en) Ophthalmic solutions viscosified with tamarind seed polysaccharide
US4271144A (en) Dextran composition for controlling corneal hydration
US20150031629A1 (en) Ophthalmic formulation derived from silk protein
CN104981234A (en) Artificial tears comprising sodium hyaluronate and carboxymethylcellulose
JP4870944B2 (en) Ophthalmic composition
JPH11500032A (en) Biodegradable eye shield
US20050043271A1 (en) Heparin-containing ophthalmic agent
JP2010065055A (en) Contact lens loading or preserving agent and agar-containing ophthalmic solution
DE60205913T2 (en) OPHTHALMIC PREPARATION WITH N-ACETYLCYSTONE FOR THE TREATMENT OF DRY EYES
US4597965A (en) Method and composition for controlling corneal hydration
WO2004011544A1 (en) Ophtalmic compositions
HOLLY Artificial tear formulations
WO2000030609A1 (en) Aqueous ophthalmic formulations comprising chitosan
CN109833294B (en) Lomefloxacin hydrochloride eye drops and preparation process thereof
BG64740B1 (en) Use of glycogen polysaccharide as active component for the production of ophthalmic solution
JP4263418B2 (en) Thermal gelation artificial tears
WO2017191041A1 (en) Ophthalmic composition comprising a synergistic combination of glycogen and hyaluronic acid or a salt thereof
RU2340327C1 (en) Ophthalmologic gel and method of its preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2494449

Country of ref document: CA

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP